67N0 Stock Chart & Stats
€0.32
<€0.01(1.06%)
At close: 4:00 PM EST
€0.32
<€0.01(1.06%)
Day’s Range― - ―
52-Week Range€0.15 - €0.47
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€374.69M
Enterprise Value€3.62K
Total Cash (Recent Filing)€1.06B
Total Debt (Recent Filing)€1.49B
Price to Earnings (P/E)4.6
Beta0.35
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding2,014,126,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.17
Price to Sales (P/S)1.67
P/FCF Ratio11.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Profitability InflectionThe sharp 2025 shift to meaningful revenue and solid operating profitability indicates the company has recently converted its biologics activities into an earnings-generating business. If maintained, this higher-margin base can support reinvestment in drug development, manufacturing, and commercialization over the next several quarters.
Positive Cash GenerationPositive operating and free cash flow, together with free cash flow close to reported net income, provides constructive evidence that 2025 profits were supported by cash conversion. This improves the company’s ability to fund operations and development internally rather than relying entirely on external financing.
Meaningful Capital BaseA substantial equity base and moderate debt-to-equity ratio provide a financial foundation for a biologics company whose returns depend on continued development and commercialization investment. This capital position can offer flexibility to support growth initiatives, even though recent borrowing warrants monitoring.
Bears Say
Unproven Earnings DurabilityThe 2025 earnings improvement follows a long period of inconsistent results, including several years of losses and periods with zero reported revenue. That history makes it difficult to establish a dependable earnings trend, so the company must demonstrate that the recent commercial and profit step-up is repeatable.
Sharp Debt IncreaseThe substantial move from near-zero debt to roughly 1.49B changes the company’s financial risk profile and introduces greater obligations alongside its recent growth. Even with moderate debt-to-equity overall, higher borrowings can reduce flexibility if profitability or cash generation weakens.
Cash Flow Stability RiskThe 2025 cash-flow improvement is encouraging, but it represents a reversal from several years of materially negative cash generation. Because the company has not yet shown consistent free cash flow across periods, future funding needs and the durability of internally generated cash remain important structural concerns.
Genor Biopharma Holdings Limited News
67N0 FAQ
What was Genor Biopharma Holdings Limited’s price range in the past 12 months?
Genor Biopharma Holdings Limited lowest stock price was €0.15 and its highest was €0.47 in the past 12 months.
What is Genor Biopharma Holdings Limited’s market cap?
Genor Biopharma Holdings Limited’s market cap is €374.69M.
When is Genor Biopharma Holdings Limited’s upcoming earnings report date?
Genor Biopharma Holdings Limited’s upcoming earnings report date is Mar 31, 2027 which is in 183 days.
How were Genor Biopharma Holdings Limited’s earnings last quarter?
Genor Biopharma Holdings Limited released its earnings results on Aug 28, 2026. The company reported -€0.004 earnings per share for the quarter.
Is Genor Biopharma Holdings Limited overvalued?
According to Wall Street analysts Genor Biopharma Holdings Limited’s price is currently Overvalued.
Does Genor Biopharma Holdings Limited pay dividends?
Genor Biopharma Holdings Limited does not currently pay dividends.
What is Genor Biopharma Holdings Limited’s EPS estimate?
Genor Biopharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genor Biopharma Holdings Limited have?
Genor Biopharma Holdings Limited has 2,014,126,200 shares outstanding.
What happened to Genor Biopharma Holdings Limited’s price movement after its last earnings report?
Genor Biopharma Holdings Limited reported an EPS of -€0.004 in its last earnings report. Following the earnings report the stock price went down -1.242%.
Which hedge fund is a major shareholder of Genor Biopharma Holdings Limited?
Currently, no hedge funds are holding shares in DE:67N0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally. Its key investigational medicines include GB242, an infliximab (Remicade) biosimilar. This drug is purposed for the treatment of various conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric Crohn's disease, and fistulizing Crohn's disease. Another prominent candidate is GB491 (lerociclib), an oral CDK4/6 inhibitor currently undergoing Phase III clinical trials for hormone receptor-positive (HR+)/HER2- breast cancer. Additionally, GB492, a stimulator of interferon genes (STING) agonist, is in Phase 1/2 clinical development, with expectations of synergistic effects when combined with GB226 for solid tumor treatment. The company's pipeline also encompasses GB221, a HER2 monoclonal antibody (mAb) designed to mimic trastuzumab (Herceptin); geptanolimab (GB226), a novel PD-1 mAb; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb, which is in Phase I clinical trials; and GB261, also in Phase I clinical trials for B-cell non-Hodgkin Lymphoma. Furthermore, its product candidates in clinical trials for cancer treatment include GB262, GB264, GB265, and GB266. Originally named JHBP (CY) Holdings Limited, the company adopted its current moniker, Genor Biopharma Holdings Limited, in June 2021. Founded in 2007, the firm maintains its headquarters in Shanghai, China.
Technical Analysis
Antengene Corporation Limited
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Mabpharm Limited
―
SinoMab Bioscience Ltd.
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―